GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: The ADDITION-PRO Study

Diabetes

Volumn 64, Issue 7, 2015, Pages 2513-2525

  Faerch, Kristine ^a   Torekov, Signe S ^b,c   Vistisen, Dorte ^a   Johansen, Nanna B ^a,b   Witte, Daniel R ^e   Jonsson, Anna ^b   Pedersen, Oluf ^b   Hansen, Torben ^b   Lauritzen, Torsten ^d   Sandbaek, Annelli ^e   Holst, Jens Juul ^b,c   Jørgensen, Marit E ^a  

^a STENO DIABETES CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Danish Diabetes Academy   (Denmark)

^e Section of General Practice   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; GLUCOSE BLOOD LEVEL;

AGE; AGED; ARTICLE; B LYMPHOCYTE; BODY MASS; BODY WEIGHT; CELL FUNCTION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HORMONE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SEX; UNFOLDED PROTEIN RESPONSE; WAIST CIRCUMFERENCE; ANALYSIS; BLOOD; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; SEXUAL DEVELOPMENT;

AGE FACTORS; AGED; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MALE; MIDDLE AGED; OBESITY; PREDIABETIC STATE; SEX CHARACTERISTICS; WAIST CIRCUMFERENCE;

EID: 84962109423     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1751     Document Type: Article

References (53)

1. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986;63:492-498
2. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52
3. Vaag AA, Holst JJ, Vølund A, Beck-Nielsen HB. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)- evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 1996;135:425-432
4. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagonlike peptide-1 (GLP-1) in type 2 diabetes: What is up, what is down? Diabetologia 2011;54:10-18
5. Calanna S, Christensen M, Holst JJ, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: Systematic review and metaanalyses of clinical studies. Diabetologia 2013;56:965-972
6. Zhang F, Tang X, Cao H, et al. Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance. Int J Med Sci 2012;9:574-581
7. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008;57:1340-1348
8. Alssema M, Rijkelijkhuizen JM, Holst JJ, et al. Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. Eur J Endocrinol 2013;169:421-430
9. Laakso M, Zilinskaite J, Hansen T, et al.; EUGENE2 Consortium. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia 2008;51:502-511
10. Rask E, Olsson T, Söderberg S, et al. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism 2004;53:624-631
11. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-3723
12. Færch K, Vaag A, Holst JJ, Glümer C, Pedersen O, Borch-Johnsen K. Impaired fasting glycaemia vs impaired glucose tolerance: Similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia 2008;51:853-861
13. Migoya EM, Bergeron R, Miller JL, et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010;88:801-808
14. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: Cause or consequence? Gut 1996;38:916-919
15. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008;57: 678-687
16. Færch K, Borch-Johnsen K, Holst JJ, Vaag A. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: Does it matter for prevention and treatment of type 2 diabetes? Diabetologia 2009;52:1714-1723
17. Færch K, Borch-Johnsen K, Vaag A, Jørgensen T, Witte DR. Sex differences in glucose levels: A consequence of physiology or methodological convenience? The Inter99 study. Diabetologia 2010;53:858-865
18. Hutson WR, Roehrkasse RL, Wald A. Influence of gender and menopause on gastric emptying and motility. Gastroenterology 1989;96:11-17
19. Færch K, Pacini G, Nolan JJ, Hansen T, Tura A, Vistisen D. Impact of glucose tolerance status, sex, and body size on glucose absorption patterns during OGTTs. Diabetes Care 2013;36:3691-3697
20. Geer EB, Shen W. Gender differences in insulin resistance, body composition, and energy balance. Gend Med 2009;6(Suppl. 1):60-75
21. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G; Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen Detected Diabetes in Primary Care. The ADDITION study: Proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000;24(Suppl. 3):S6-S11
22. Johansen NB, Hansen AL, Jensen TM, et al. Protocol for ADDITION-PRO: A longitudinal cohort study of the cardiovascular experience of individuals at high risk for diabetes recruited from Danish primary care. BMC Public Health 2012;12:1078
23. Holst JJ. Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours. Diabetologia 1983;24:359-365
24. Erskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994;43:535-539
25. Lindgren O, Carr RD, Deacon CF, et al. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab 2011;96:2519-2524
26. Gutt M, Davis CL, Spitzer SB, et al. Validation of the insulin sensitivity index (ISI(0,120)): Comparison with other measures. Diabetes Res Clin Pract 2000;47: 177-184
27. Seltzer HS, Allen EW, Herron AL Jr, Brennan MT. Insulin secretion in response to glycemic stimulus: Relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 1967;46:323-335
28. Chia CW, Odetunde JO, Kim W, Carlson OD, Ferrucci L, Egan JM. GIP contributes to islet trihormonal abnormalities in type 2 diabetes. J Clin Endocrinol Metab 2014;99:2477-2485
29. Theodorakis MJ, Carlson O, Michopoulos S, et al. Human duodenal enteroendocrine cells: Source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 2006;290:E550-E559
30. Knop FK, Vilsbøll T, Højberg PV, et al. Reduced incretin effect in type 2 diabetes: Cause or consequence of the diabetic state? Diabetes 2007;56:1951-1959
31. Matikainen N, Bogl LH, Hakkarainen A, et al. GLP-1 responses are heritable and blunted in acquired obesity with high liver fat and insulin resistance. Diabetes Care 2014;37:242-251
32. Gjesing AP, Ekstrøm CT, Eiberg H, et al. Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits. Diabetologia 2012;55:1338-1345
33. Torekov SS, Kipnes MS, Harley RE, Holst JJ, Ehlers MR. Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:639-643
34. Torekov SS, Holst JJ, Ehlers MR. Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014;16:451-456
35. Woerle HJ, Carneiro L, Derani A, Göke B, Schirra J. The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes. Diabetes 2012;61:2349-2358
36. Sathananthan M, Farrugia LP, Miles JM, et al. Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, b-cell function, and glucose metabolism in nondiabetic subjects. Diabetes 2013;62:2752-2756
37. Sjøberg KA, Holst JJ, Rattigan S, Richter EA, Kiens B. GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle. Am J Physiol Endocrinol Metab 2014;306:E355-E362
38. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 2001;86: 3853-3860
39. Torekov SS, Ma L, Grarup N, et al.; GIANT Consortium. Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1. Diabetologia 2011;54:2820-2831
40. Verdich C, Toubro S, Buemann B, Lysgård Madsen J, Juul Holst J, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety-effect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001;25:1206-1214
41. Nathanson D, Zethelius B, Berne C, Holst JJ, Sjöholm A, Nyström T. Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease. Diabetologia 2010;53:277-280
42. Idorn T, Knop FK, Jørgensen MB, et al. Elimination and degradation of glucagonlike peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease. J Clin Endocrinol Metab 2014;99:2457-2466
43. Perreault L, Færch K. Approaching pre-diabetes. J Diabetes Complications 2014;28:226-233
44. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-E206
45. Vilsbøll T, Agersø H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003;88:220-224
46. Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsbøll T. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:737-745
47. Bak MJ, Wewer Albrechtsen NJ, Pedersen J, et al. Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): Implications for GLP-1 measurements in clinical studies. Diabetes Obes Metab 2014;16:1155-1164
48. Hjøllund KR, Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs. Diabetologia 2011;54:2206-2208
49. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005;48:612-615
50. Astrup A, Rössner S, Van Gaal L, et al.; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebocontrolled study. Lancet 2009;374:1606-1616
51. Iepsen EW, Lundgren J, Dirksen C, et al. Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss. Int J Obes (Lond). 7 October 2014 [Epub ahead of print]
52. Torekov SS, Madsbad S, Holst JJ. Obesity-an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obes Rev 2011;12:593-601
53. Wadden TA, Hollander P, Klein S, et al.; NN8022-1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low-calorie-dietinduced weight loss: The SCALE Maintenance randomized study. Int J Obes (Lond) 2013;37:1443-1451